NCT01045304 - Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer | Biotech Hunter

Enrollment

163

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

November 30, 2012

Conditions

Breast Cancer, Metastatic

Interventions

DRUG

Iniparib

"Pharmaceutical form: solution for infusion~Route of administration: intravenous"

DRUG

Gemcitabine

"Pharmaceutical form: solution for infusion~Route of administration: intravenous"

DRUG

Carboplatin

"Pharmaceutical form: solution for infusion~Route of administration: intravenous"

Trial Locations (20)

1000

Sanofi-Aventis Investigational Site Number 056001, Brussels

2145

Sanofi-Aventis Investigational Site Number 036003, Westmead

3000

Sanofi-Aventis Investigational Site Number 056002, Leuven

3052

Sanofi-Aventis Investigational Site Number 036002, Parkville

6000

Sanofi-Aventis Investigational Site Number 036001, Perth

16132

Sanofi-Aventis Investigational Site Number 380004, Genova

20133

Sanofi-Aventis Investigational Site Number 380001, Milan

21034

Sanofi-Aventis Investigational Site Number 250002, Dijon

25030

Sanofi-Aventis Investigational Site Number 250005, Besançon

28050

Sanofi-Aventis Investigational Site Number 724004, Madrid

29010

Sanofi-Aventis Investigational Site Number 724001, Málaga

31052

Sanofi-Aventis Investigational Site Number 250001, Toulouse

33076

Sanofi-Aventis Investigational Site Number 250003, Bordeaux

33100

Sanofi-Aventis Investigational Site Number 380003, Udine

41100

Sanofi-Aventis Investigational Site Number 380002, Modena

46010

Sanofi-Aventis Investigational Site Number 724003, Valencia

75231

Sanofi-Aventis Investigational Site Number 250006, Paris

75970

Sanofi-Aventis Investigational Site Number 250004, Paris

3075 EA

Sanofi-Aventis Investigational Site Number 528001, Rotterdam

08035

Sanofi-Aventis Investigational Site Number 724002, Barcelona